當(dāng)前位置：首頁 JCRQ2 期刊介紹(非官網(wǎng))

EndocrineSCIE

國際簡稱：ENDOCRINE 參考譯名：內(nèi)分泌

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：1355-008X; E-ISSN：1559-0100; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：Springer US; 出版語言：English; 出版周期：12 issues per year; 出版年份：1995; 研究方向：ENDOCRINOLOGY & METABOLISM

評(píng)價(jià)信息：: 影響因子：3; H-index：74; CiteScore指數(shù)：6.5; SJR指數(shù)：0.844; SNIP指數(shù)：0.941

發(fā)文數(shù)據(jù)：: Gold OA文章占比：24.97%; 研究類文章占比：80.70%; 年發(fā)文量：342; 自引率：0.0540...; 開源占比：0.2095; 出版撤稿占比：0.0026...; 出版國人文章占比：0.17; OA被引用占比：0.1500...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Endocrine期刊介紹

Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.

Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.

Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.

期刊簡介Endocrine期刊介紹

《Endocrine》自1995出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約1.5月
醫(yī)學(xué)
ENDOCRINOLOGY & METABOLISM
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Endocrine Cite Score數(shù)據(jù)

CiteScore：6.5
SJR：0.844
SNIP：0.941

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Endocrinology, Diabetes and Metabolism	Q2	79 / 244	67%
大類：Medicine 小類：Endocrinology	Q2	48 / 128	62%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Endocrine 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Endocrine JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q2	88 / 186	53%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q2	91 / 186	51.34%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計(jì)

國家/地區(qū)數(shù)量
Italy322
CHINA MAINLAND247
USA140
Brazil58
England53
France44
Greece44
GERMANY (FED REP GER)41
Sweden38
Spain37

本刊中國學(xué)者近年發(fā)表論文

1、Machine learning-based prediction of diagnostic markers for Graves' orbitopathy
Author: Cai, Yunying; Su, Heng; Si, Yongting; Ni, Ninghua

Journal: ENDOCRINE. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s12020-023-03349-z
2、Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study
Author: Wang, Shiwei; Wang, Yu; Zhu, Li; He, Liang; Lv, Mutian; Zhang, Hao; Wang, Haoyu; Zhang, Fan; Lai, Yaxin; Li, Yushu; Shan, Zhongyan; Teng, Weiping

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 113-124. DOI: 10.1007/s12020-022-03186-6
3、Mutation screening of eight genes and comparison of the clinical data in a Chinese cohort with congenital hypothyroidism
Author: Li, Liangshan; Li, Xiaole; Wang, Xiaoyu; Han, Mengmeng; Zhao, Dehua; Wang, Fang; Liu, Shiguo

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 125-134. DOI: 10.1007/s12020-022-03188-4
4、2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease
Author: Parameswaran, Rajeev; de Jong, Mechteld Christine; Kit, James Lee Wai; Sek, Kathleen; Tran Quang Nam; Tran Viet Thang; Nguyen Thy Khue; Than Than Aye; Phone Myint Tun; Cole, Timothy; Miller, Julie A.; Villa, Michael; Khiewvan, Benjapa; Sirinvaravong, Sirinart; Sin, Yong Lit; Muhammad, Rohaizak; Jap, Tjin Shing; Agrawal, Amit; Rajput, Rajesh; Fernando, Ranil; Sumanatilleke, Manilka; Suastika, Ketut; Shong, Young Kee; Lang, Brian; Bartalena, Luigi; Yang, Samantha Peiling

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 135-142. DOI: 10.1007/s12020-022-03193-7
5、Global Burden of osteoarthritis associated with high body mass index in 204 countries and territories, 1990-2019: findings from the Global Burden of Disease Study 2019
Author: Zhao, Gaichan; Zhu, Shijie; Zhang, Faxue; Zhang, Xupeng; Zhang, Xiaowei; Li, Tianzhou; Li, Dejia; Zhu, Wei

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 60-71. DOI: 10.1007/s12020-022-03201-w
6、Roxadustat improves renal osteodystrophy by dual regulation of bone remodeling
Author: Li, Luyao; Li, Afang; Gan, Liangying; Zuo, Li

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 180-189. DOI: 10.1007/s12020-022-03199-1
7、Clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis
Author: Yin, Lei; Hou, Shuang; Hou, Li-Li; Pu, Chen-Chen

Journal: ENDOCRINE. 2023; Vol. 79, Issue 2, pp. 331-341. DOI: 10.1007/s12020-022-03200-x
8、The combination of early identification, chemotherapy, and autologous stem cell transplantation obtained favorable outcomes in unilateral primary adrenal lymphoma: A case report
Author: Huang, Lu; Shuai, Xiao; Zhang, Tingting; Kuang, Pu; Zhang, Dan; Chen, Tao; Tian, Haoming; Xiang, Bing; Ren, Yan

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 49-54. DOI: 10.1007/s12020-022-03138-0